Please assess the completion status of the following clinical trial:

Trial Title: Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed and/or refractory DLBCL,not HSCT candidates. Pts must have failed standard of care (SOC) therapy w/rituximab plus CHOP or its equivalent \& not considered hematopoietic stem cell transplant (HSCT) candidates based on investigator's discretion~* Pts must have measurable disease radiographically on CT and/or PET scans and/or bone marrow biopsy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~* Age ≥18 years. No upper limit of age~* Life expectancy of 6 months or more based on investigator's best estimate.~* Pts able to read, understand, \& sign informed consent~* Evidence of CD20 positivity in treated pts, using flow or immunohistochemistry.~* Pts will be stratified based on bulk of disease (bulk defined as any area w/ more than 5cm in greatest dimension)~* Pts must agree to an acceptable form of birth control~Exclusion Criteria:~* Other histologies of non-Hodgkin's lymphoma (NHL)~* Known central nervous system (CNS) involvement with NHL~* Known HIV positive status~* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.~* Corticosteroid use is allowed as long as it is for non-lymphoma related causes such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD).~* Pts w/prior malignancies are allowed as long as they are in remission \& their last treatment for such malignancy is 2 years prior to enrollment or more. Pts w/non-melanoma skin cancers that have received adequate therapy prior to enrollment \& women w/history of cervical cancers are allowed.~* Significant concurrent uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurologic, cerebral, or psychiatric disease.~* Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per the investigator's assessment).~* Adequate bone marrow function by virtue of having Platelets \>50,000/ul \& absolute neutrophil count (ANC) \>1000/ul is required unless low counts are attributed to diffuse bone marrow infiltration with NHL as documented with a bone marrow biopsy exam.~* Pts with creatinine \>2.0 times the upper limit of normal will be excluded unless they have a normal creatinine clearance-estimated or measure 12 or 24 hour creatinine clearance of \<60 mL/min~* Pts w/total bilirubin \>1.5 times upper limit of normal will be excluded, unless due to DLBCL involvement of liver or a known history of Gilbert's disease.~* Pts with aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/Alkaline phosphatase (Alk Phos) \>2.5 times upper limit of normal~* Previous tx with Ofatumumab~* Prior exposure to an investigational agent within 4-weeks from starting Ofatumumab~* History of significant cerebrovascular disease or event w/significant symptoms or sequelae~* Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to randomization, congestive heart failure (NYHA III-IV), \& arrhythmia unless controlled by therapy, w/exception of extra systoles or minor conduction abnormalities.~* Positive serology for hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive \& regardless of HBsAb status, a HB DNA test will be performed and if positive the subject to be excluded. Note: If HBcAb positive and HBsAb positive, which is indicative of a past infection, subject can be included~* Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the result.~* Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at screening, including women whose last menstrual period was less than 1 year prior to screening, unable or unwilling to use adequate contraception from study start to 1 year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Type: EXPERIMENTAL): The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).